ProfessionalHybridActive

Certificate in Psychedelic-Assisted Therapies (CPAT)™

The Certificate in Psychedelic-Assisted Therapies (CPAT)™ is a hybrid professional training program for healthcare and mental health professionals and other eligible practitioners. It covers the safe and effective delivery of psychedelic-assisted therapies in clinical settings, with a focus on psilocybin, MDMA and keta

Schedule

Next cohort: Oct 1, 2026

113 hours

Enrollment

Price on request

Decision Summary

Best fit
Prescribing psychiatrists, healthcare and mental health professionals, and other eligible practitioners who may deliver psychedelic-assisted therapies as part of a multidisciplinary team.
Format
Hybrid
Time commitment
113 hours
Credential signal
CPD

Upcoming Cohort

Start date: October 1, 2026

Course Overview

Delivered by Mind Medicine Australia, CPAT™ combines online learning with face-to-face residential intensives and provides more than 127 CPD-accredited hours of training. The program is designed for prescribing psychiatrists and other mental health professionals involved in delivering psychedelic-assisted therapies as part of multidisciplinary teams. The curriculum covers best-practice approaches to psychedelic-assisted therapy, with a focus on psilocybin, MDMA and ketamine-assisted therapy. Training is delivered by an international faculty of practitioners and researchers in the field. Graduates may gain access to professional experience at the Mind Medicine Australia Clinic and Centre of Excellence, as well as alumni professional development, supervision and peer support opportunities.

Who is this for?

Prescribing psychiatrists, healthcare and mental health professionals, and other eligible practitioners who may deliver psychedelic-assisted therapies as part of a multidisciplinary team.

Prerequisites

Eligibility is required, but specific prerequisite criteria are not provided in the source text.

About the Provider

Mind Medicine Australia is a national nonprofit that has played a defining role in Australia's regulated psychedelic-access environment. Its public work spans rescheduling advocacy, implementation support, clinician training, patient support funding, and ongoing efforts to broaden access pathways. Although it is broader than a pure patient group, it is too important to leave out of Blossom's access map. The organization now reports active involvement in regulatory follow-through, rollout improvements, patient support, and collaboration with End Wise on palliative-care expansion.

View all Mind Medicine Australia courses

Course FAQ

Who is this course for?

Prescribing psychiatrists, healthcare and mental health professionals, and other eligible practitioners who may deliver psychedelic-assisted therapies as part of a multidisciplinary team.

Are there prerequisites?

Eligibility is required, but specific prerequisite criteria are not provided in the source text.

What is the format and time commitment?

Format: Hybrid. Time commitment: 113 hours.

How much does it cost?

This listing does not have a public price yet. Check the provider website for current tuition, fees, or application-based pricing.

Does it offer a certificate or CE/CME credit?

The listing includes a certificate signal. Accreditation note: CPD. Confirm credential eligibility directly with the provider before enrolling.

When does the next cohort start?

The listed next cohort date is 2026-10-01.

Is this course currently available?

The current listing status is Active. Use the provider website for the latest enrollment status.

Related Courses

View all courses